[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2627 followers Created: 2025-07-17 12:32:31 UTC $PRAX Praxis Precision Medicines granted FDA Breakthrough Therapy Designation for Relutrigine to treat seizures related to SCN2A and SCN8A Developmental and Epileptic Encephalopathies. More Info: $XBI $IBB $XPH $PPH  XXX engagements  **Related Topics** [$pph](/topic/$pph) [$xph](/topic/$xph) [$ibb](/topic/$ibb) [$xbi](/topic/$xbi) [more info](/topic/more-info) [breakthrough](/topic/breakthrough) [$prax](/topic/$prax) [Post Link](https://x.com/OzmosiHealth/status/1945823930666934771)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Ozmosi @OzmosiHealth on x 2627 followers
Created: 2025-07-17 12:32:31 UTC
$PRAX Praxis Precision Medicines granted FDA Breakthrough Therapy Designation for Relutrigine to treat seizures related to SCN2A and SCN8A Developmental and Epileptic Encephalopathies.
More Info: $XBI $IBB $XPH $PPH
XXX engagements
Related Topics $pph $xph $ibb $xbi more info breakthrough $prax
/post/tweet::1945823930666934771